Flash is not installed!Download Adobe Flash viewer

Making products better together

Novozymes Biopharma develops and manufactures high-quality, animal-free, and regulatory-compliant recombinant ingredients and technologies to provide pharmaceutical and medical device manufacturers the knowledge-based solutions needed to address the challenges in developing innovative, safer, and more consistent final products.

The company's large-scale manufacturing facilities worldwide are run to cGMP Q7 quality standards to ensure that customers receive the highest level of product quality and consistency, as well as the security of long-term supply. Novozymes’ customer-integrated approach combines the company’s scientific know-how and the specific needs of customers to deliver improved products and performance.

Dedicated to scientific innovation
With over 25 years experience in the pharmaceutical industry, Novozymes is the world leader in the supply of recombinant products and technologies to the medical device and drug delivery market. Currently, 14% of the company’s total revenue is spent on R&D projects demonstrating a commitment to scientific innovation.

By combining Novozymes’ unique knowledge around our biological solutions such as recombinant albumin and hyaluronic acid with the specific application knowledge of our customers, we work with companies to deliver improved performance and safety for next generation of medical device and pharmaceutical products.

LATEST NEWS

› Novozymes finalizes sale of Novozymes Biopharma Sweden. Read more

› Novozymes Biopharma supplies R-Tech Ueno with Albucult^® for use in unique dry eye therapy. Read more

› To sharpen focus on areas such as hyaluronic acid and rAlbumin, Novozymes will divest Novozymes Biopharma Sweden and related AMP projects. Read more

› Novozymes enters into an exclusive supplier agreement to supply Recombuminfor Type 2 Diabetes drug. Read more